COVID-19 and the community oncologist

Thursday, April 16, 2020

How are community oncologists adapting to the COVID-19 pandemic? Podcast host David H. Henry, MD, of Pennsylvania Hospital in Philadelphia, explores this question with Matthew Lonergan, MD, of Willamette Valley Cancer Institute (WVCI) and Research Center in Eugene, Ore.

Dr. Lonergan explains how WVCI is attempting to minimize staff exposure to COVID-19, how physicians there are dealing with the transition to telemedicine, and how a lack of resources has affected WVCI. Dr. Lonergan and Dr. Henry also discuss how the COVID-19 pandemic has changed research, tumor boards, and other meetings. And the pair compare the response to the current pandemic with the response to HIV and the Spanish flu.

Disclosures:

Dr. Henry reported having no financial disclosures relevant to this episode. Dr. Lonergan reported having no financial disclosures relevant to this episode.

* * *

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: podcasts@mdedge.com

Interact with us on Twitter: @MDedgehemonc

David Henry on Twitter: @davidhenrymd

Ilana Yurkiewicz on Twitter: @ilanayurkiewicz

How to Listen

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.



More Episodes from Blood & Cancer

View All Episodes

Close